Medicaid Managed Care and the 2025 CMS Final Rule: How Carved-Out Specialty Drugs Will Impact State Rebates and Access
In April 2024, the Centers for Medicare & Medicaid Services (CMS) finalized new Medicaid Managed Care regulations, with key provisions kicking in on July 9, 2025. Among the biggest shifts: how states handle “carved-out” drugs, especially high-cost specialty therapies, when tallying up federal and state rebate responsibilities. Both states and managed care organizations (MCOs) now have to coordinate rebate claims with tighter accuracy to avoid duplicate discounts or lost reimbursement dollars. The accounting just got real.
How Specialty Drug Carve-Outs Work
A carved-out drug is one that an MCO excludes from its pharmacy benefit, leaving the state’s fee-for-service (FFS) system to pay the claim directly. Many states took this route for expensive therapies such as adalimumab (Humira, AbbVie) and infliximab (Remicade, Janssen Biotech) so they could control rebates and utilization a bit more closely. These drugs typically sit on the highest specialty tier in managed Medicaid formularies, often requiring prior authorization or a step therapy sequence before approval.
Historically, states got better rebate returns through the federal Medicaid Drug Rebate Program when these drugs were carved out. The trouble was the messy handoff between FFS claims and managed care data, leading to unclaimed rebates and duplicate submissions. The 2025 CMS rule changes that by forcing states to document, down to the claim level, what’s carved out and what isn’t. Rebate chasing gets standardized.
CMS Clarifications on Rebates
CMS found that poor coordination in this area caused state Medicaid programs to lose millions each year. Under the new rule, states must file explicit documentation identifying carved-out drugs and the rebate source for each claim. That means tighter audits, more consistent federal reporting, and, let’s be honest, a heavier administrative lift for state Medicaid agencies and MCOs alike.
| Policy Element | Pre-2025 Rule | Post-2025 Rule |
|---|---|---|
| Carved-Out Drug Reporting | Optional or inconsistent across states | Mandatory unified reporting to CMS |
| Rebate Coordination | Handled separately by MCOs and states | Joint accountability to prevent duplicate or missed rebates |
| Effective Date | Previous guidance varied | July 9, 2025, nationwide |
Access and Administrative Implications
For patients, carved-out drugs often come with extra layers of authorization, which can slow down therapy starts. Pharmacists and MCO case managers may have to reroute claims or troubleshoot coverage confusion more frequently. Benefit managers, meanwhile, will be syncing files and claims feeds with state systems to make sure rebate tracking lines up with the new requirements.
According to the Kaiser Family Foundation (KFF), specialty drugs now consume more than half of Medicaid pharmacy spending while making up less than 2% of prescriptions. No wonder CMS tightened the screws on rebate oversight. Some states carved out entire categories, like biologics or clotting factors for hemophilia, and will now have to weigh if the administrative savings were really worth the trade-offs in patient access. Personally, I think some of those cost-control instincts were right, but execution got messy.
Medical and Insurance Disclaimer: This content is for informational purposes only and should not be taken as medical, legal, or insurance advice. Coverage decisions depend on actual policy language and professional counsel.